MIB Agents OsteoBites and osTEAo

MIB Agents Osteosarcoma
  • 5.0 (5)
  • MEDICINE
  • UPDATED BIWEEKLY

Each week, MIB Agents talks with the leaders and innovators in osteosarcoma surgery, research, treatment and advocacy. Questions are taken during the webinar and are included in each podcast. More information is available at www.mibagents.org

  1. 5D AGO

    High-throughput characterization of pathobiological responses in osteosarcoma tumors treated with LRRC15-targeted radiotherapy to uncover curative co-treatment approaches

    Osteosarcoma Webinar Series: David Ulmert, MD, PhD, an Associate Professor at UCLA, discusses his OutSmarting Osteosarcoma funded work (Because of Sydney) on high-throughput characterization of pathobiological responses in osteosarcoma tumors treated with LRRC15-targeted radiotherapy to uncover curative co-treatment approaches. Dr. Ulmert will discuss his lab's work investigating how osteosarcoma responds to LRRC15-targeted radiotherapy, with patient translation anticipated this year. Using high-throughput technologies, the team will identify biomarkers, predictive models, and key transcriptional regulators driving the TGFβ–LRRC15 axis. He will review how radiopathobiological changes and immune reprogramming are being mapped to uncover druggable events and inform co-treatment strategies, accelerating near-term impact on patient studies and next-generation therapeutic development. Dr. David Ulmert is an expert in oncology and biotechnology, specializing in cancer biomarkers and targeted therapies. His research focuses on antigens secreted by luminal tissues as novel cancer-specific targets and circulating biomarkers. He developed high-affinity antibodies against androgen receptor-regulated enzymes hK2 and PSA, now in clinical trials across the US, Europe, and Australia—in collaboration with Janssen—for radioimmunotheranostics, CAR-T therapy, and bispecific targeting. His lab also developed DUNP19, an LRRC15-targeting antibody licensed to Lantheus, with a Phase 1 trial in osteosarcoma planned for 2025. Dr. Ulmert leads UCLA’s Preclinical Theranostics Program and conducts population-based studies on cancer biomarkers and risk factors with international collaborators. He is widely recognized for advancing prostate cancer research and translational immunotheranostics.

    1h 18m

  2. JAN 26

    osTEAo: New Year, Same Cancer

    The first episode of 2026 keeps it real about what the New Year actually feels like when osteosarcoma is still part of everyday life. Mia and Sammy are joined by Sloane and Mackenzie to talk through pain, recovery, scans, insurance stress, and the emotional weight January can bring. There’s no pressure to have it all figured out—just honest conversation, shared experiences, and hope focused on small, bite-sized goals and taking things one day at a time.

    44 min

  3. JAN 16

    Next generation dual-CAR gamma delta T cells for the treatment of pediatric osteosarcoma

    Osteosarcoma Webinar Series: Joseph Skeate, PhD, an Assistant Professor at the University of Minnesota, discusses his OutSmarting Osteosarcoma funded work (Because of Annaleigh) on next generation dual-CAR gamma delta T cells for the treatment of pediatric osteosarcoma. In this presentation, Dr. Skeate will provide an overview of the next-generation genome engineering strategies deployed for this project and share updates on the development of a gamma-delta chimeric antigen receptor (CAR) T cell therapy for treating osteosarcoma. He will describe how the team is combining non-viral transposon insertion of a CAR transgene with targeted gene modification using an Adenine Base Editor to enhance T cell function in the presence of suppressive factors characteristic of osteosarcoma tumors. Dr Joseph Skeate is an Assistant Professor in the Division of Pediatric Hematology/Oncology at the University of Minnesota. He obtained his PhD in Medical Biology from the University of Southern California Keck School of Medicine. Following his doctoral work, he completed a postdoctoral fellowship at the University of Minnesota under the mentorship of Drs Branden Moriarity and Beau Webber. During this time, he developed a hyperactive transposon system and deployed novel genome engineering approaches using Cas9 systems, creating a powerful toolkit for rapid non-viral engineering and preclinical testing of primary human cells. Leveraging his background and expertise in immunology and genome engineering, his lab now focuses on developing next-generation cellular therapies for rare pediatric disease, including osteosarcoma.

    1 hr

  4. JAN 8

    Insights from the Musculoskeletal Tumor Society (MSTS) December 2025 Annual Meeting

    Osteosarcoma Webinar Series: Izuchukwu Ibe, MD, a musculoskeletal oncologist, Associate Professor, and Residency Program Director at the University of Mississippi Medical Center joins us on OsteoBites to discuss insights and highlights from the Musculoskeletal Tumor Society (MSTS) December 2025 Annual Meeting, December 3-5 in Mexico City. Dr. Ibe is a Musculoskeletal Oncologist with a residency from Yale and a Fellowship from the University of Toronto. He is passionate about educating patients and families with a sarcoma diagnosis and channels this through his Sarcoma Insights podcasts. He enjoys soccer and spending time with his family.

    39 min

  5. 12/12/2025

    Results of a phase II trial of olaparib in combination with ceralasertib in patients with recurrent and unresectable osteosarcoma

    Results of a phase II trial of olaparib in combination with ceralasertib in patients with recurrent and unresectable osteosarcoma Osteosarcoma Webinar Series: Katie Janeway, MD and Suzanne Forrest, MD join us on OsteoBites to discuss results of a phase II trial of olaparib in combination with ceralasertib in patients with recurrent and unresectable osteosarcoma. Dr. Janeway received her MD and MMSc from Harvard Medical School. She completed her pediatrics residency and her Pediatric Hematology-Oncology fellowship at Boston Children’s Hospital and Dana-Farber Cancer Institute. She is an Associate Professor of Pediatrics, a Senior Physician who cares for young people with sarcoma, and Director of Clinical Genomics. Dr. Janeway’s research is focused on precision oncology and bone sarcomas. She leads clinical trials both as an independent investigator and as the Chair of the Children’s Oncology Group (COG) Bone Tumor Committee. The Janeway Laboratory leads several studies, which have enrolled and sequenced more than 2,500 patients with childhood cancers. They are using this data to deepen the understanding of clinical and genomic factors explaining prognosis and treatment response, and resistance, with a focus on sarcomas. In collaboration with Count Me In, the group is innovating patient partnerships in sarcoma research.Dr. Forrest completed her medical school training at Yale University, followed by pediatrics training in the Boston Combined Residency Program. She then pursued a pediatric oncology fellowship at Dana-Farber Cancer Institute / Boston Children’s Hospital. Currently, she serves as an Assistant Professor of Pediatrics at Harvard Medical School and an Attending Physician in the Department of Hematology/Oncology at Dana-Farber / Boston Children’s Cancer and Blood Disorders Center. Her research focuses on developing novel clinical trials that utilize cancer genomics to guide treatment strategies for pediatric solid tumors. After a short presentation on this research, they will take questions from attendees. Share your questions in advance with us at Christina@MIBAgents.org.

    56 min

  6. 12/05/2025

    Ongoing chromothripsis underpins osteosarcoma genome complexity and clonal evolution

    Osteosarcoma Webinar Series: Isidro Cortés-Ciriano will discuss his work studying how ongoing chromothripsis underpins osteosarcoma genome complexity and clonal evolution.

    1h 1m

  7. 11/20/2025

    osTEAo: Navigating Loss in the AYA Community

    In this episode of osTEAo, Mia and Sammy — joined by Mackenzie and Alejandro — open up about the many forms of loss: losing friends, losing health, and losing parts of themselves as life shifts after cancer. They talk about how grief shows up in changing abilities, in memories, and in the quiet moments where life feels different than before. Through honest conversation about rituals, storytelling, and the ways grief softens over time, they explore how remembrance can heal and how connection helps carry the weight. Despite the heaviness, the group finds hope in shared stories, laughter, and the idea that while grief is intertwined with love, no one has to navigate it alone.

    55 min

  8. 11/10/2025

    Synergy of ATM and PARP Inhibitors in Pediatric Osteosarcoma

    Osteosarcoma Webinar Series: Janeala Morsby, PhD, a postdoctoral associate at St. Jude Children’s Research Hospital, discusses her OutSmarting Osteosarcoma funded work focused on exploring the mechanism of synergy of the dual inhibition of ATM and PARP for the treatment of pediatric osteosarcoma.Janeala Morsby hails from the beautiful island of Jamaica, where she was born and raised in Port Antonio, Portland. Her journey to the United States began when she received a full honors scholarship to attend Claflin University, where she completed her Bachelor of Science in Biochemistry, summa cum laude. She then went on to complete her PhD at the University of Notre Dame under the supervision of Dr. Bradley Smith. At the University of Notre Dame, her work focused on the detection of hypoxia in cancer cell models, in addition to diagnostics and imaging. She is now a postdoctoral associate at St. Jude Children’s Research Hospital (SJCRH) in Dr. Lillian Guenther’s lab. At SJCRH, her work focuses on exploring the mechanism of synergy of the dual inhibition of ATM and PARP for the treatment of pediatric osteosarcoma. She is very passionate about the proposed research project and hopes that the findings of the proposed work will be beneficial to pediatric osteosarcoma patients.

    50 min
See All (204)

Ratings & Reviews

5
out of 5
5 Ratings

About

Each week, MIB Agents talks with the leaders and innovators in osteosarcoma surgery, research, treatment and advocacy. Questions are taken during the webinar and are included in each podcast. More information is available at www.mibagents.org

Information

  • Creator
    MIB Agents Osteosarcoma
  • Years Active
    2020 - 2026
  • Episodes
    204
  • Rating
    Explicit
  • Copyright
    © MIB Agents Osteosarcoma
  • Show Website
    MIB Agents OsteoBites and osTEAo